# Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer

> **NCT01373294** · PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 17 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Bacille Calmette-Guerrin (BCG)
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT01373294
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11-30
- **Primary completion:** 2015-01-09
- **Final completion:** 2018-12-10
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2019-08-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01373294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01373294, "Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT01373294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*